Drug Therapy Clinical Trial
Official title:
Comparison of the Efficacy of Sensor-augmented Pump Therapy Versus Hybrid Closed-loop Glucose Management (MiniMed670G™) in Patients With Type 1 Diabetes at Home in a Randomized Controlled Trial
Verified date | June 2021 |
Source | Kinderkrankenhaus auf der Bult |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Closed loop technology has been shown to reduce both hypoglycemia and hyperglycemia, as well as reduce glycemic variability. Sensor augmented pump (SAP) therapy means the addition of alerts according to high or low glucose values as well as trend arrows showing actual glucose trends to pump therapy. This Hybrid closed loop (HCL) system provides several additional effects compared to SAP therapy: according to actual and predicted sensor glucose values, the insulin therapy can be adopted automatically by pump: in case of high values (or predicted) more insulin will be administered, in case of low values (or predicted) the insulin infusion will be decreased a suspended and resumed again. So the HCL provides a lot more automatic functions to keep glucose in target compared to SAP. The aim of the current trial is to compare the SAP-therapy with the hybrid closed loop glucose management in patients with type 1 diabetes at home.
Status | Completed |
Enrollment | 40 |
Est. completion date | October 10, 2020 |
Est. primary completion date | October 10, 2020 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 2 Years to 14 Years |
Eligibility | Inclusion Criteria: General Inclusion Criteria 1. At time of screening: Subjects who are 2-14 years are determined by the investigator to be psychologically sound (e.g. no depression, anxiety disorder, traumatic stress disorder) in order to successfully participate in this study 2. Subject has been diagnosed with type 1 diabetes = 1 year Study-specific inclusion criteria Subjects will be considered for enrollment in the study if they meet all of the following criteria: 3. Subjects who are 2-14 years are determined by the investigator to have the appropriate, requisite support (family, caregiver or social network) to successfully participate in this study 4. Subject is willing to wear the system continuously throughout the study 5. Subject is willing to perform required sensor calibrations 6. Total daily dose of Insulin >8 U 7. Subject has an A1C value < 12.0% (as processed by Laboratory) at time of screening visit 8. Subject must be on Pump therapy for >3 months prior to Screening 9. Subject may also be on sensor augmented pump therapy. 10. If subject has celiac disease it has been adequately treated as proven by Transglutamase-Antibodies in normal range Exclusion Criteria: 1. Event of severe hypoglycemia in past 3 months (as per ISPAD Guideline Definition 2014: seizure or loss of consciousness.) 2. Subject is unable to tolerate tape adhesive in the area of sensor placement 3. Subject has any unresolved adverse skin condition in the area of sensor placement (e.g., psoriasis, rash, Staphylococcus infection) 4. Women of child-bearing potential who have a positive pregnancy test at screening or plan to become pregnant during the course of the study 5. Subject has had any of the following new diagnoses within 1 year of screening: myocardial infarction, unstable angina, coronary artery bypass surgery, coronary artery stenting, transient ischemic attack, cerebrovascular accident, angina, congestive heart failure, ventricular rhythm disturbances or thromboembolic disease 6. Subject has a clinical significant abnormality (out of reference range, as processed by Laboratory) in thyroid-stimulating hormone (TSH) at time of screening visit 7. Subjects suffering from Morbus Addison, heart failure >NYHA II, chronic pulmonal disease >GOLD II, chronic arterial insuffiency, known cancer disease, diabetic kidney disease, diabetic autonom or peropheral neuropathy 8. Subject tests positive in the drug screen 9. Subject has taken any oral, injectable, or IV steroids within 8 weeks prior time of screening visit, or plans to take any oral, injectable, or IV steroids during the course of the study; furthermore patients using antipsychotic drugs, antidepressive, ß-blocking agents are not permitted to participate 10. Subject is actively participating in an investigational study (drug or device) wherein he/she has received treatment from an investigational study drug or investigational study device in the last 4 weeks 11. Subject is currently abusing illicit drugs 12. Subject is currently abusing prescription drugs 13. Subject is currently abusing alcohol 14. Subject is using pramlintide (Symlin) at time of screening 15. Subject has a history of visual impairment which would not allow subject to participate in the study and perform all study procedures safely, as determined by the investigator 16. Subject has elective surgery planned that requires general anesthesia during the course of the study 17. Subject has a sickle cell disease, hemoglobinopathy; or has received red blood cell transfusion or erythropoietin within 3 months prior to time of screening 18. Subject plans to receive red blood cell transfusion or erythropoietin over the course of study participation 19. Subject diagnosed with current eating disorder such as anorexia or bulimia 20. Subject has been diagnosed with chronic kidney disease that results in chronic anemia 21. Subject is on dialysis 22. Subjects known for factitial hypoglycemia or possible suicidal tendencies. 23. Patients who are unwilling or unable to perform a minimum of four blood glucose tests per day. 24. People who are unwilling or unable to maintain contact with their healthcare professional. Patients whose vision or hearing does not allow cognition of pump signals and alarms. |
Country | Name | City | State |
---|---|---|---|
Germany | Kinder - und Jugendkrankenhaus AUF DER BULT | Hannover |
Lead Sponsor | Collaborator |
---|---|
Kinderkrankenhaus auf der Bult |
Germany,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Reduction of Sensor Glucose | Time in Range (% of Sensor Glucose 70-180 mg/dL) (SAP period vs Hybrid Closed loop) | 6 month |
Status | Clinical Trial | Phase | |
---|---|---|---|
Enrolling by invitation |
NCT02588560 -
Viral Load Changes in Lymphoma Patients With HCV Infection After Chemotherapy
|
N/A | |
Completed |
NCT05366621 -
Post-fracture Medication and Mortality
|
||
Recruiting |
NCT03487939 -
Neoadjuvant FOLFOXIRI Chemotherapy in Resectable Liver Metastasis of Colorectal Cancer
|
Phase 2 | |
Recruiting |
NCT04478838 -
"Extended" (Alternate Day) Antipsychotic Dosing
|
Phase 4 | |
Recruiting |
NCT05322967 -
Effect of Chronotherapy on Blood Pressure - Time of Intake of Blood Pressure Lowering Drugs
|
N/A | |
Not yet recruiting |
NCT01131429 -
A Chinese Randomized Crossover Study of Erlotinib Versus Docetaxel/Cisplatin in Previously Untreated Stage IIIB/IV Lung Adenocarcinoma With EGFR Mutations
|
Phase 2 | |
Recruiting |
NCT06223568 -
Phase II Trial of Neoadjuvant Chemotherapy (NAC) Alone or in Combination With Immunotherapy Vaccine PRGN-2009 in Subjects With Newly Diagnosed HPV-Associated Oropharyngeal (Head and Neck) Cancer
|
Phase 2 | |
Completed |
NCT04627077 -
Livestrong Cancer Institutes' Patient Reported Outcomes Study
|
||
Recruiting |
NCT06009965 -
Efficacy of IST Combined With TPO-RA in the Treatment of AA and Establishment of a Recurrence Prediction System
|
Phase 4 | |
Completed |
NCT03551457 -
Potential Therapeutic Response In Urogenital Tumors
|
||
Completed |
NCT04095104 -
Adjunct Phentermine + Topiramate After Bariatric Surgery in 12-24 Year Olds
|
Phase 2 | |
Recruiting |
NCT04996732 -
Long-term Survivorship of Discharged Patients With Malignant Tumor Based on Single-institutional Cancer Registry
|
||
Not yet recruiting |
NCT05246722 -
Registry Study of Pharmacotherapy and Clinical Outcomes in Elderly Patients With Coronary Heart Disease (PHARM-ageing)
|
||
Completed |
NCT04141657 -
Safety Analysis of Antimicrobial Pharmacotherapy in Intensive Care Unit at Pediatric Hospital
|
||
Not yet recruiting |
NCT04184583 -
Registry Study on Drug Therapy and Clinical Outcomes in Patients With Acute Coronary Syndrome
|
||
Completed |
NCT04493905 -
Effects of Anesthetic Techniques on Time to Start of Adjuvant Chemotherapy Following Surgery for Colorectal Cancer
|
||
Completed |
NCT01199393 -
Genetic Polymorphisms Predict Chemotherapeutic Outcomes in Patients With Metastatic Breast Cancer
|
N/A | |
Recruiting |
NCT03484221 -
Totally Neoadjuvant FOLFOXIRI + Short-course Radiation + XELOX in Patients With Locally Advanced Rectal Cancer
|
Phase 2 | |
Recruiting |
NCT03484195 -
Neoadjuvant FOLFOXIRI Chemotherapy in Patients With Locally Advanced Colon Cancer
|
Phase 2 | |
Completed |
NCT00122122 -
Randomized Controlled Trial of Enhanced Pharmacy Care in Older Veteran Outpatients
|
Phase 3 |